Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts.

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

Recursion Pharmaceuticals (RXRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Alec Stranahan from Bank of America Securities maintained a ...

In a report released today, Steven Mah from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The company’s shares closed today at $6.64. Mah covers the ...

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...

Recursion Pharma is an AI-driven drug developer that boasts supercomputers designed to shorten drug development timelines and enhance successful outcomes. Many such companies have raised substantial ...

Sentiment on the company has improved following solid clinical trial results from one of its pipeline drugs earlier this month.

Recursion Pharmaceuticals' stock experienced a 10.06% surge on Monday, indicating strong investor confidence in the company's innovations. The completion of BioHive-2 marks a pivotal moment for ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...